LeonaBio Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat LeonaBio de winst en omzet met respectievelijk 3.9% en 75.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 50.6% per jaar.

Belangrijke informatie

3.9%

Groei van de winst

50.59%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	14.5%
Inkomstengroei	75.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	08 May 2026

Recente toekomstige groei-updates

Recent updates

Analyse-artikel • Feb 16

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma (NASDAQ:ATHA) said an independent data monitoring committee recommended to continue a phase 2/3 trial of fosgonimeton (ATH-1017) to treat patients with mild-to-moderate Alzheimer's disease (AD). The committee made the recommended after an interim efficacy and futility analysis of the study, dubbed LIFT-AD, the company added. In addition, the panel decided that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 people without background therapy (acetylcholinesterase inhibitors), the trial will be well powered for the main goal given the preliminary effect size seen, according to the company. The main goal of the trial is Global Statistical Test, a tool for measuring cognition and function. Athira noted that data from a phase 2 study called ACT-AD had showed a favorable safety profile and suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton without background therapy. ATHA +2.49% to $3.29 premarket Oct. 17

Seeking Alpha • Aug 15

Athira Pharma GAAP EPS of -$0.65

Athira Pharma press release (NASDAQ:ATHA): Q2 GAAP EPS of -$0.65. Cash, cash equivalents and investments were $282.2 million as of June 30, 2022, compared with $319.7 million as of December 31, 2021.

Analyse-artikel • Aug 09

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Jun 22

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the proposed pathway and drug candidate ATH-1017, and I expected this would happen. The company's shares are falling severely on the primary endpoint miss. Simply stated, if the primary endpoint would have been cognition in the monotherapy group, then the results would have been seen as successful, which is why I believe there is potential to be a new Alzheimer's drug in the making here.

Analyse-artikel • May 08

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyse-artikel • Jan 11

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jun 29

Athira Pharma: What, Exactly, Did The CEO Do?

CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.

Analyse-artikel • May 24

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analyse-artikel • Feb 08

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyse-artikel • Dec 18

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

The big shareholder groups in Athira Pharma, Inc. ( NASDAQ:ATHA ) have power over the company. Institutions often own...

Winst- en omzetgroeiprognoses

NasdaqCM:LONA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	N/A	-141	-135	N/A	2
12/31/2027	N/A	-119	-112	N/A	2
12/31/2026	N/A	-115	-88	N/A	3
3/31/2026	N/A	-129	-52	-52	N/A
12/31/2025	N/A	-106	-46	-46	N/A
9/30/2025	N/A	-38	-52	-52	N/A
6/30/2025	N/A	-60	-71	-71	N/A
3/31/2025	N/A	-80	-86	-86	N/A
12/31/2024	N/A	-97	-97	-97	N/A
9/30/2024	N/A	-109	-97	-97	N/A
6/30/2024	N/A	-113	-98	-98	N/A
3/31/2024	N/A	-116	-100	-100	N/A
12/31/2023	N/A	-118	-101	-101	N/A
9/30/2023	N/A	-121	-90	-90	N/A
6/30/2023	N/A	-108	-88	-88	N/A
3/31/2023	N/A	-102	-83	-82	N/A
12/31/2022	N/A	-96	-74	-72	N/A
9/30/2022	N/A	-82	-77	-75	N/A
6/30/2022	N/A	-77	-66	-64	N/A
3/31/2022	N/A	-67	-54	-52	N/A
12/31/2021	N/A	-55	-45	-43	N/A
9/30/2021	N/A	-46	-38	-36	N/A
6/30/2021	N/A	-39	-37	-35	N/A
3/31/2021	N/A	-27	-33	-30	N/A
12/31/2020	N/A	-20	-26	-24	N/A
9/30/2020	N/A	-13	-15	-14	N/A
6/30/2020	N/A	-6	-6	-6	N/A
3/31/2020	N/A	-6	-4	-4	N/A
12/31/2019	N/A	-5	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat LONA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat LONA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat LONA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat LONA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat LONA volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van LONA naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/11 20:57
Aandelenkoers aan het einde van de dag	2026/05/08 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

LeonaBio, Inc. wordt gevolgd door 7 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Esther Lannie Hong	Berenberg
Eric Schmidt	Cantor Fitzgerald & Co.
Jason Butler	Citizens JMP Securities, LLC

LeonaBio Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 46% to US$4.00

Price target increased by 23% to US$9.25

Price target decreased by 33% to US$7.83

Price target increased to US$11.75

Price target increased to US$11.75

Price target decreased to US$15.40

Recent updates

LeonaBio, Inc. announced that it has received $89.724073 million in funding

Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer

Athira Pharma, Inc. Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate

New major risk - Share price stability

Athira Pharma, Inc. announced that it expects to receive $89.724073 million in funding

Insufficient new directors

New minor risk - Share price stability

Athira Pharma, Inc., Annual General Meeting, May 29, 2025

New major risk - Market cap size

High number of new directors

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Price target decreased by 46% to US$4.00

Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease

New major risk - Financial position

Independent Chairwoman of the Board recently bought US$100k worth of stock

Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Price target increased by 23% to US$9.25

Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer

Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

CFO & Chief Business Officer recently bought US$192k worth of stock

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer

Athira Pharma, Inc. Announces CFO Changes

Independent Director recently bought US$60k worth of stock

Price target decreased by 33% to US$7.83

Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Chief Financial Officer recently bought US$142k worth of stock

Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Independent Chairwoman of the Board recently bought US$99k worth of stock

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Price target increased to US$11.75

High number of new and inexperienced directors

Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis

Price target increased to US$11.75

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

Athira Pharma GAAP EPS of -$0.65

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Price target decreased to US$15.40

Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma, Inc. Announces New Board Appointments

Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

Richard A Kayne Communicates with Athira Pharma Inc

High number of new and inexperienced directors

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc., Annual General Meeting, May 19, 2022

Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Independent Chairman of the Board recently bought US$105k worth of stock

Richard A. Kayne Sends Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc. Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Athira Pharma, Inc. Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease